Morgan Stanley
GNOM icon

Morgan Stanley’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Morgan Stanley’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.3K Buy
488
+1
+0.2% +$46 ﹤0.01% 6701
2025
Q4 		$22.1K Sell
487
-2,048
-81% -$90.8K ﹤0.01% 6663
2025
Q3 		$98.4K Sell
2,535
-1
-0% -$36 ﹤0.01% 6158
2025
Q2 		$85.5K Sell
2,536
-109
-4% -$3.45K ﹤0.01% 6187
2025
Q1 		$84.1K Buy
2,645
+44
+2% +$1.67K ﹤0.01% 6092
2024
Q4 		$101K Sell
2,601
-235
-8% -$9.87K ﹤0.01% 6055
2024
Q3 		$128K Sell
2,836
-464
-14% -$20.7K ﹤0.01% 5903
2024
Q2 		$138K Sell
3,300
-92
-3% -$3.85K ﹤0.01% 5841
2024
Q1 		$154K Sell
3,392
-2,890
-46% -$132K ﹤0.01% 5819
2023
Q4 		$290K Buy
6,282
+3,141
+100% +$128K ﹤0.01% 5804
2023
Q3 		$128K Sell
3,141
-75
-2% -$3.42K ﹤0.01% 5768
2023
Q2 		$156K Sell
3,216
-237
-7% -$11.9K ﹤0.01% 5750
2023
Q1 		$170K Buy
3,453
+2,493
+260% +$128K ﹤0.01% 5783
2022
Q4 		$48.6K Sell
960
-1,947
-67% -$100K ﹤0.01% 6303
2022
Q3 		$146K Buy
2,907
+45
+2% +$2.54K ﹤0.01% 5890
2022
Q2 		$140K Hold
2,862
– – ﹤0.01% 6090
2022
Q1 		$172K Sell
2,862
-81
-3% -$5.11K ﹤0.01% 6001
2021
Q4 		$234K Sell
2,943
-110
-4% -$9.24K ﹤0.01% 5983
2021
Q3 		$271K Buy
3,053
+81
+3% +$7.59K ﹤0.01% 5837
2021
Q2 		$296K Sell
2,972
-194
-6% -$17.2K ﹤0.01% 5818
2021
Q1 		$284K Buy
3,166
+2,160
+215% +$213K ﹤0.01% 5461
2020
Q4 		$95K Buy
1,006
+925
+1,142% +$77.4K ﹤0.01% 5931
2020
Q3 		$6K Buy
+81
New +$5.8K ﹤0.01% 6408

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
AA
Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Morgan Stanley's GNOM Position: Q1 2026 in Review

Morgan Stanley increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 0.21% in Q1 2026, buying an estimated $46 and bringing the position to 488 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6701.

Morgan Stanley first reported a position in GNOM in Q3 2020 and has held it in 23 quarters since. The position peaked at $296K in Q2 2021. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

  • Morgan Stanley held 488 shares of Global X Genomics & Biotechnology ETF worth $21.3K as of Q1 2026.
  • Morgan Stanley bought 1 Global X Genomics & Biotechnology ETF share in Q1 2026, an estimated $46.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6701 holding.
  • Morgan Stanley first reported a position in Global X Genomics & Biotechnology ETF in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Global X Genomics & Biotechnology ETF position peaked at $296K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.